Skip to main content
Livermore
Livermore
ZHEN

Novo Holdings A/S

SEC CIK
0001388325
Latest filing
Aug 14, 2026

The latest 13F from Novo Holdings A/S covers Q2 2026 (filed Aug 14, 2026): 25 long positions worth $1.72B. The top 10 holdings make up 73.8% of the portfolio, and the largest is Edgewise Therapeutics, Inc. (EWTX) at 12.7%. Livermore has 24 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
6
Est. +$393.9M
Added
2
Est. +$2.97M
Reduced
8
Est. −$89.0M
Sold out
3
Est. −$81.8M

Top 5 holdings

Share of this quarter's portfolio value

  1. EWTXEdgewise Therapeutics, Inc.
    12.7%$217.4MHistory
  2. ASMLASML Holding NV
    11.0%$188.9MHistory
  3. COAGHemab Therapeutics Holdings, Inc.
    9.0%$153.6MHistory
  4. BNBROOKFIELD Corp
    8.7%$149.5MHistory
  5. MPLTMapLight Therapeutics, Inc.
    7.7%$132.1MHistory

Share of portfolio

Top 5 holdings and the other 20 positions, by share of portfolio value

  1. EWTX12.7%
  2. ASML11.0%
  3. COAG9.0%
  4. BN8.7%
  5. MPLT7.7%
  6. Other 20 positions50.9%

Biggest buys

New and added positions, by estimated amount bought

  1. COAGHemab Therapeutics Holdings, Inc.
    +$153.6MNewHistory
  2. AVLNAvalyn Pharma Inc.
    +$127.8MNewHistory
  3. FNDFloor & Decor Holdings, Inc.
    +$47.3MNewHistory
  4. ALMSAlumis Inc.
    +$31.0MNewHistory
  5. DYNDyne Therapeutics, Inc.
    +$21.3MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. COAGHemab Therapeutics Holdings, Inc.
    +8.95 pp0.0% → 9.0%History
  2. AVLNAvalyn Pharma Inc.
    +7.45 pp0.0% → 7.5%History
  3. FNDFloor & Decor Holdings, Inc.
    +2.76 pp0.0% → 2.8%History
  4. ALMSAlumis Inc.
    +1.80 pp0.0% → 1.8%History
  5. DYNDyne Therapeutics, Inc.
    +1.24 pp0.0% → 1.2%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. APGEApogee Therapeutics, Inc.
    −$37.9MSold outHistory
  2. BMRNBiomarin Pharmaceutical Inc
    −$37.3MSold outHistory
  3. MIRMMirum Pharmaceuticals, Inc.
    −$23.4MReducedHistory
  4. AVBPArriVent BioPharma, Inc.
    −$15.4MReducedHistory
  5. ELVNEnliven Therapeutics, Inc.
    −$14.2MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. APGEApogee Therapeutics, Inc.
    −3.07 pp3.1% → 0.0%History
  2. BMRNBiomarin Pharmaceutical Inc
    −3.02 pp3.0% → 0.0%History
  3. MIRMMirum Pharmaceuticals, Inc.
    −2.24 pp9.9% → 7.7%History
  4. CRNXCrinetics Pharmaceuticals, Inc.
    −1.68 pp4.6% → 2.9%History
  5. PCVXVaxcyte, Inc.
    −1.34 pp4.0% → 2.7%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$1.72B
+$480.8M (+39.0%) vs. prior quarter
Positions
25
+3 vs. prior quarter
Top 10 concentration
73.8%
Top 10 as share of value
Turnover
11.6%
Q2 2026, one quarter
Average holding period
10.2 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $2.42B (Q1 2021)

Q1 2021: $2.42BQ2 2021: $2.25BQ3 2021: $1.93BQ4 2021: $2.11BQ1 2022: $1.90BQ2 2022: $2.03BQ3 2022: $2.08BQ4 2022: $1.60BQ1 2023: $1.40BQ2 2023: $1.29BQ3 2023: $1.35BQ4 2023: $1.50BQ1 2024: $1.45BQ2 2024: $1.85BQ3 2024: $2.01BQ4 2024: $1.65BQ1 2025: $1.31BQ2 2025: $1.42BQ3 2025: $1.55BQ4 2025: $1.29BQ1 2026: $1.23BQ2 2026: $1.72B
Q1 2021Q2 2026
13F filings of Novo Holdings A/S by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202625$1.72BEWTXASMLCOAGvs. Q1 2026SEC
Q1 2026May 15, 202622$1.23BEWTXBNASMLvs. Q4 2025SEC
Q4 2025Feb 17, 202624$1.29BBNEWTXASMLvs. Q3 2025SEC
Q3 2025Nov 14, 202527$1.55BVanguard Morningstar Total Stock Market ETFBNASMLvs. Q2 2025SEC
Q2 2025Aug 14, 202529$1.42BVanguard Morningstar Total Stock Market ETFBNASMLvs. Q1 2025SEC
Q1 2025May 15, 202531$1.31BVanguard Morningstar Total Stock Market ETFBNEWTXvs. Q4 2024SEC
Q4 2024Feb 14, 202534$1.65BVanguard Morningstar Total Stock Market ETFBNTEMvs. Q3 2024SEC
Q3 2024Oct 24, 202437$2.01BVanguard Morningstar Total Stock Market ETFTEMBNvs. Q2 2024SEC
Q2 2024Aug 20, 2024Amended38$1.85BVanguard Morningstar Total Stock Market ETFBNTEMvs. Q1 2024SEC
Q1 2024May 15, 202435$1.45BASMLBNCRMvs. Q4 2023SEC
Q4 2023Feb 14, 202436$1.50BBNASMLCRMvs. Q3 2023SEC
Q3 2023Nov 14, 202340$1.35BBNASMLCRMvs. Q2 2023SEC
Q2 2023Aug 14, 202341$1.29BASMLCRMLNZAvs. Q1 2023SEC
Q1 2023May 15, 202347$1.40BASMLCRMBAMvs. Q4 2022SEC
Q4 2022Feb 14, 202348$1.60BSYKASMLSTEvs. Q3 2022SEC
Q3 2022Nov 14, 202252$2.08BVanguard Morningstar Total Stock Market ETFSYKCTLTvs. Q2 2022SEC
Q2 2022Aug 15, 202254$2.03BVanguard Morningstar Total Stock Market ETFCTLTSYKvs. Q1 2022SEC
Q1 2022May 27, 2022Amended51$1.90BVanguard Morningstar Total Stock Market ETFBAMBSXvs. Q4 2021SEC
Q4 2021Feb 14, 202248$2.11BVanguard Morningstar Total Stock Market ETFExscientia PLCBAMvs. Q3 2021SEC
Q3 2021Nov 15, 202149$1.93BVanguard Morningstar Total Stock Market ETFBAMBSXvs. Q2 2021SEC
Q2 2021Aug 16, 202154$2.25BVanguard Morningstar Total Stock Market ETFBAMMORFvs. Q1 2021SEC
Q1 2021May 17, 202151$2.42BVanguard Morningstar Total Stock Market ETFEWTXMORF–SEC

13D and 13G filings

Companies where Novo Holdings A/S reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

4 companies, largest stake first.

Companies where Novo Holdings A/S owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
COAGHemab Therapeutics Holdings, Inc.13G9.00%4.18M sharesNewAug 14, 20261 filingAug 14, 2026SEC
AVLNAvalyn Pharma Inc.13G8.80%3.88M sharesNewAug 14, 20261 filingAug 14, 2026SEC
FDMT4D Molecular Therapeutics, Inc.13G/A6.40%3.65M shares−0.40 ppfrom 6.80%Oct 20, 20252 filingsFeb 17, 2026SEC
OBXObsidian Therapeutics, Inc.13G5.10%3.12M sharesNewAug 10, 20261 filingAug 10, 2026SEC

Latest filings

119 filings on file made by Novo Holdings A/S or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Novo Holdings A/S
CompanyFiled (ET)FormStakeChangeEvent dateFiling
COAGHemab Therapeutics Holdings, Inc.Aug 14, 20265:05 PM ET13G9.00%4.18M sharesNewJun 30, 2026SEC
AVLNAvalyn Pharma Inc.Aug 14, 20265:03 PM ET13G8.80%3.88M sharesNewJun 30, 2026SEC
OBXObsidian Therapeutics, Inc.Aug 10, 20264:21 PM ET13G5.10%3.12M sharesNewAug 3, 2026SEC
MPLTMapLight Therapeutics, Inc.Jul 31, 20269:25 AM ET13D/A4.90%2.09M shares−3.50 ppfrom 8.40%Below 5%Jul 30, 2026SEC
LNZALanzaTech Global, Inc.May 15, 20264:28 PM ET13G/A1.60%158.1K shares–Below 5%Mar 31, 2026SEC
EWTXEdgewise Therapeutics, Inc.Apr 27, 20264:49 PM ET13D/A4.90%5.35M shares–Below 5%Apr 23, 2026SEC
FDMT4D Molecular Therapeutics, Inc.Feb 17, 20266:55 PM ET13G/A6.40%3.65M shares−0.40 ppfrom 6.80%Dec 31, 2025SEC
EVOEvotec SEFeb 17, 20266:54 PM ET13G/A0.00%0 shares−5.30 ppfrom 5.30%Below 5%Dec 31, 2025SEC
IOBTIO Biotech, Inc.Jan 23, 20267:05 PM ET13D/A3.30%2.47M shares−4.00 ppfrom 7.30%Below 5%Jan 21, 2026SEC
EVOEvotec SENov 14, 20256:30 PM ET13G/A5.30%9.41M shares–Sep 30, 2025SEC
ZBIOZenas BioPharma, Inc.Nov 14, 20256:29 PM ET13G/A4.70%2.00M shares−0.60 ppfrom 5.30%Below 5%Sep 30, 2025SEC
MPLTMapLight Therapeutics, Inc.Nov 4, 20254:21 PM ET13D8.40%3.69M sharesNewOct 28, 2025SEC
FDMT4D Molecular Therapeutics, Inc.Oct 20, 20255:12 PM ET13G6.80%3.17M sharesNewOct 13, 2025SEC
DMRADamora Therapeutics, Inc.Oct 9, 20254:29 PM ET13D/A0.00%0 shares−6.50 ppfrom 6.50%Below 5%Oct 7, 2025SEC
DMRADamora Therapeutics, Inc.Sep 25, 20254:49 PM ET13D/A6.50%86.6K shares−1.10 ppfrom 7.60%Sep 23, 2025SEC
IOBTIO Biotech, Inc.Aug 19, 20255:09 PM ET13D/A7.30%4.98M shares–Aug 11, 2025SEC
AVBPArriVent BioPharma, Inc.Aug 14, 20254:59 PM ET13G/A4.90%1.87M shares−0.30 ppfrom 5.20%Below 5%Jun 30, 2025SEC
ZBIOZenas BioPharma, Inc.Apr 1, 20259:47 PM ET13G5.30%2.21M sharesNewMar 25, 2025SEC
AVBPArriVent BioPharma, Inc.Feb 14, 20259:00 PM ET13G5.20%1.75M sharesNewFeb 7, 2025SEC
DMRADamora Therapeutics, Inc.Jan 16, 20259:43 PM ET13D/A7.60%99.9K shares–Aug 29, 2024SEC